Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cure ADSSL1 is a non-profit research foundation and patient advocacy organization dedicated to finding a cure for ADSSL1-deficient myopathy, a rare and progressive muscle-wasting disease. The foundation accelerates therapeutic development by funding high-impact research, including gene therapy and small molecule drug discovery programs. Cure ADSSL1 also focuses on essential clinical readiness activities, such as establishing a global patient registry and conducting natural history studies to identify disease biomarkers. By fostering collaborations between academic scientists, clinicians, and industry partners, the organization aims to bridge the gap between basic research and clinical application. Their ultimate goal is to provide life-changing treatments for individuals affected by this genetic neuromuscular disorder.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CureADSSL1.